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Abstract
Background Vasopressor-induced hypertension is routinely
indicated for prevention and treatment of cerebral vaso-
spasm (CVS) after subarachnoid haemorrhage (SAH).
Mechanisms underlying patients’ clinical improvement
during vasopressor-induced hypertension remain incom-
pletely understood. The aim of this study was to evaluate
angiographic effects of normovolaemic Norepinephrine
(NE)-induced hypertension therapy on the rabbit basilar
artery (BA) after SAH.
Methods Cerebral vasospasm was induced using the one-
haemorrhage rabbit model; sham-operated animals served as
controls. Five days later the animals underwent follow-up
angiography prior to and during NE-induced hypertension.
Changes in diameter of the BA were digitally calculated in
mean µm ± SEM (standard error of mean).
Findings Significant CVS of 14.2% was documented in
the BA of the SAH animals on day 5 compared to the
baseline angiogram on day 0 (n=12, p<0.01), whereas the
BA of the control animals remained statistically un-
changed (n=12, p>0.05). During systemic administration
of NE, mean arterial pressure increased from 70.0±
1.9 mmHg to 136.0±2.1 mmHg in the SAH group
(n=12, p<0.001) and from 72.0±3.1 to 137.8±1.3 in the
control group (n=12, p<0.001). On day 5 after SAH, a
significant dilatation of the BA in response to norepi-
nephrine could be demonstrated in both groups. The
diameter of the BA in the SAH group increased from
640.5±17.5µm to 722.5±23.7µm (n=12, p<0.05; ). In
the control group the diameter increased from 716.8±15.5
µm to 779.9±24.1µm (n=12, p<0.05).
Conclusion This study demonstrated that NE-induced
hypertension causes angiographic dilatation of the BA in
the SAH rabbit model. Based on these observations, it can
be hypothesised that clinical improvement during
vasopressor-induced hypertension therapy after SAH might
be explained with cerebral vasodilatation mechanisms that
lead to improvement of cerebral blood flow.
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Introduction
Delayed cerebral vasospasm (CVS) is considered the
principal cause of high morbidity and mortality in patients
undergoing treatment of subarachnoid haemorrhage [27],
leading to delayed ischaemic neurological deficits (DIND),
permanent neurological damage and death. It mainly
transiently occurs 4–8 days after onset of SAH [5, 9, 14,
24]. Despite decades of research, the pathogenesis of CVS
remains unclear [22].
Progress has been made in the management of CVS.
Routine protocols combine early surgery with systemic
administration of the calcium channel antagonist, nimodi-
pine, and hyperdynamic therapy. As a result, the mortality
and morbidity due to CVS have been reduced to 5–10%,
compared to about 20% rates in the early 1980s [24].
Hyperdynamic therapy consists of haemodilution, hyper-
volaemia and induced hypertension (HHH), and is routinely
administered despite some controversy [12, 14, 19, 24, 28].
The efficacy of haemodilution and hypervolaemia in
particular has been seriously questioned lately [13, 17, 23,
24]. A relative risk of extracranial complications has been
reported, and includes pulmonary oedema, hyponatraemia
and congestive heart failure, to mention the most common.
Induced hypertension, although associated with the possible
risk of rebleeding from the aneurysm, has been evaluated as
being safe [6, 16]. Vasopressors such as norepinephrine
(NE) and phenylephrine are most commonly used clinically
to induce hypertension during HHH therapy after SAH
[14]. An improvement in patients’ cerebral blood flow
(CBF) and, thus, cerebral perfusion and clinical outcome
has been documented in several studies [1, 8, 10, 17, 18,
23]. However, the mechanism underlying patients’ en-
hanced clinical status remains incompletely understood.
The aim of this study was to evaluate angiographic effects
of normovolaemic NE-induced hypertension therapy on the
rabbit BA after SAH.
Materials and methods
Study design
The protocol of this study was reviewed and approved by
the Swiss Institutional Animal Care and Use Committee as
meeting the Swiss guidelines for laboratory animal use
(approval #16/06). Twenty-four adult New Zealand White
rabbits of either sex weighing 2.6–3.6 kg were randomly
assigned to two experimental groups (12 animals each).
One of these groups underwent experimental SAH on
day 0, while the other served as a sham-operated control.
All surgical procedures were performed under sterile
conditions.
Angiography
After induction of general anaesthesia by intramuscular
administration of ketamine (30 mg/kg) and xylazine
(6 mg/kg), digital subtraction angiography (DSA) was
performed on day 0 prior to SAH and on day 5 post SAH
and sham-operation, respectively, in accordance with our
protocol recently reported [15]. In brief, the rabbits’ left
(day 0) or right (day 5) subclavian artery was micro-
surgically cannulated using a catheter that was fixed distal
to the vertebral branch. Subsequently, images of the
vertebro-basilar system were obtained by rapid sequential
DSA using intra-arterial bolus injection of non-ionic
iopamidol (0.6 ml/kg) as contrast agent. Meanwhile, the
arterial blood gas status was analysed to monitor ventilation
parameters. The average diameter of the BA was digitally
Fig. 1 Box plot showing the absolute change of the BA in diameter in
SAH animals compared to controls (in µm ± SEM): Baseline
angiography on day 0 vs. pre-treatment follow up on day 5 vs.
angiography during NE-induced hypertension on day 5. (*p<0.05; ns
non-significant)
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calculated in μm using the automatic measurement tool of
the ImagePro Discovery® analysis software (MediaCyber-
netics, Bethesda, MD, USA).
Cerebral vasospasm model
Following baseline DSA on day 0, the rabbits underwent
the one-haemorrhage SAH rabbit model, as reported
earlier by our group [4, 15]. Briefly, after draining of
1.0 ml cerebrospinal fluid, an equal amount of unhepari-
nised autologous arterial blood was injected into the
cerebro-medullary cistern under microscopic view to
imitate SAH in order to induce CVS. An equal amount of
isotonic saline solution was used instead in controls. Post-
surgical pain relief was managed by subcutaneous admin-
istration of buprenorphine (0.1–0.2 mg/kg) for up to 36 h
after SAH.
Induction of hypertension
After performance of pre-treatment follow-up DSA on day 5,
peripheral hypertension was induced by continuous central
arterial administration of NE (2.3–4.0μg*min*
−1kg−1) in
dose-dependency to monitored blood pressure, the mean
arterial pressure (MAP) in particular. Under constant
conditions, a second follow-up DSA was performed to
register any change of the BA diameter during peripheral
hypertension.
Drugs
The following drugs were used: buprenorphinum (Temge-
sic® 0.3 mg/ml, Essex Chemie, Lucerne, Switzerland);
iopamidol (Iopamiro® 300 mg/ml, Bracco, Milano, Italy);
isoflurane (Forene® 99%, Abbott Laboratories, Abbott
Park, IL, USA); ketamine HCl (Ketalar® 50 mg/ml, Pfizer
AG, Zurich, Switzerland); norepinephrine (Noradrenalin
Bichsel®, Bichsel, Interlaken, Switzerland); sodium thio-
pental (Pentothal® 25 mg/ml, Abbott Laboratories, Abbott
Park, IL, USA); and xylazine HCl (Xylapan® 20 mg/ml,
Vetoquinol AG, Bern, Switzerland).
Statistical methods
Values were expressed as a mean in each group ± SEM (n =
number of animals). Statistical significance between 2
means and multiple means was determined by parametric
One-way-ANOVA and Bonferroni’s multiple comparisons
post-testing, respectively. Statistical significance was con-
Table 1 The effect of NE-induced hypertension on the rabbits’ BA diameter in summary
Exp group n State of treatment BA diameter in µm (mean ± SEM) ∆ BA diameter
to previous state
MAP in mmHg (mean ± SEM) ∆ mean MAP to
previous state
in µm in % in mmHg in %
control 12 baseline–day 0 740.6±10.4 73.9±2.8
pretreatment–day 5 716.8±15.5 23.8 3.2 72.0±3.1 1.9 2.5
NE-treatment–day 5 779.9±24.1 63.1* 8.9 137.8±1.3 65.8*** 91.4
SAH 12 baseline–day 0 746.2±20.5 73.7±2.1
pretreatment–day 5 640.5±17.5 105.7** 14.2 70.0±1.9 3.7 5.0
NE-treatment–day 5 722.5±23.7 82.0* 12.9 136.0±2.1 66.0*** 94.3
(*p<0.05, **p<0.01, ***p<0.001)
Fig. 2 Box plot showing the absolute MAP changes of the SAH
group compared to controls (in mmHg ± SEM): During baseline
angiography on day 0 vs. pre-treatment follow up on day 5 vs. NE-
induced hypertension on day 5. (*p<0.05; ns non-significant)
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sidered if the P-value was less than 0.05 (p<0.05) in
context of the 95% confidence intervals of the difference
examined (95% CI of diff).
Results
Arteriographic changes of the vessel diameter
On day 5 after SAH the diameter of the BAwas significantly
narrowed by 14.2±2.8%, to 640.5±17.5µm in pre-treatment
state compared to the baseline angiogram (746.2±20.5µm) on
day 0 (n=12, p<0.01, 95% CI of diff: 37.4–175.0µm). In
contrast, the BA diameter in controls was on average 740.6±
10.4µm wide on the baseline angiogram on day 0 and
remained statistically unchanged to the pre-treatment state on
day 5 (716.8±15.5µm) (n=12, p>0.05, 95% CI of
diff: −34.7µm to 82.3µm). The SAH and control groups
were, thus, significantly different from each other in diameter
five days after the induction of SAH and the sham operation,
respectively, prior to the administration of NE (p<0.05, 95%
CI of diff: 10.0–143.5µm) (Fig. 1).
Continuous administration of NE on day 5 in the SAH
group caused significant arteriographic dilation of the spastic
vessel by 12.97% to 722.5±23.7µm in diameter (n=12,
p<0.05, 95% CI of diff: 13.8–150.2µm). In controls, the
administered NE significantly dilated the BA by 8.86%, to
779.9±24.1µm in relation to 716.8±15.5µm in the pre-
treatment state (n=12, p<0.05, 95% CI of diff:
4.6–121.6µm). During continuous administration of NE on
day 5, the groups did not statistically differ in BA diameter
(p>0.05, 95% CI of diff: −9.4µm to124.1µm) (Fig. 1). The
relative dilating effect on the BA diameter in the SAH group
(+12.97±2.52%) was also statistically insignificant in com-
parison to the relative effect of NE-induced hypertension
detected in the BA of controls (+8.86±2.66%, n=12, p>
0.05, 95% CI of diff: −3.67 to 11.8) (Table 1).
The initial blood gas parameters, such as pO2
(54.8±1.7 mmHg), pCO2 (51.9±1.2 mmHg) and pH
(7.38±0.01), did not change compared to the values
monitored during follow-up angiography on day 5 in both
the SAH (p>0.05) and control groups (p>0.05), and did
not statistically differ between the two groups (p>0.05).
Assessed changes of arterial blood pressure
During the baseline angiography on day 0, the MAP of the
SAH group was at a level of 73.7±2.1 mmHg (n=12). It
remained statistically unchanged in comparison to its MAP
pre-treatment assessment 5 days later (70.0±1.9 mmHg, p>
0.05, 95% CI of diff: −3.2 to 10.5 mmHg). Correspondingly,
controls showed similar MAP values. They started at a level
of 73.9±2.8 mmHg at baseline on day 0 and remained
statistically unchanged at 72.0±3.1 mmHg in pre-treatment
state on day 5 (n=12, p>0.05, 95% CI of diff: −6.4 mmHg
to 10.3 mmHg). In SAH animals, continuous administration
of NE on day 5 induced a highly significant increase in MAP
to 136.0±2.1 mmHg (n=12, p<0.001, 95% CI of diff:
59.2–72.9 mmHg) compared to their pre-treatment state.
Corresponding constant hypertension at a MAP level of
137.8±1.3 mmHg was achieved in controls (n=12); it also
showed a highly significant MAP rise compared to the time
prior to the administration of NE on day 5 (p<0.001, 95% CI
of diff: 57.5–74.1 mmHg) (Fig. 2).
The MAP level of the SAH group was similar to the
level in controls throughout the pre-NE state within the
5 days the experiment lasted (p>0.05). There was also no
significant difference detected in the extent of induced
hypertension between those two groups (n=12 each, p>
0.05, 95% CI of diff: −6.2 mmHg to 9.7 mmHg) (Table 1).
Discussion
Since it was first described in the 1970s, several studies
have focused on the efficacy of vasopressor-induced
hypertension therapy after SAH. The potency in both
Fig. 3 The Hagen–Poiseuille law of laminar flow is extrapolated to
CBF and put in context to our results
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prevention and treatment of CVS has been examined. The
efficacy of the therapy as a preventive approach remains
controversial due to conflicting data reported. While some
authors observed in non-controlled, non-randomised trials
that induced hypertension as part of HHH was beneficial in
preventing CVS and DIND [20, 26, 29], Egge et al. was not
able to repeat these finding in his prospective, controlled
and randomised setting [3]. The preventive efficacy is thus
considered questionable, with the need of induced hyper-
tension therapy having been examined separately in a large,
randomised, controlled clinical trial [14, 28].
However, vasopressor-induced hypertension is used
routinely in the clinic and is—in contrast to the preventive
approach—recommended for the treatment of clinical or
angiographic CVS which is resistant to nimodipine [14,
24]. Support is based on several studies: three of them
included additional hyperdynamic targets as part of HHH
and concluded that there were benefits in the treatment of
CVS in terms of enhancing CBF or improving clinical
outcome [1, 8, 18]. Another five studies examined induced
hypertension therapy separately from the haemodilutional
and hypervolaemic approach and came to similar conclu-
sions regarding its efficacy in terms of cerebral perfusion or
neurological deficits (Table 2) [2, 7, 17, 21, 23]. In fact,
hypertension has been demonstrated to be superior to
hypervolaemia in its effectiveness [7, 17, 23]. Due to the
lack of large, blinded, randomised and controlled trials on
its efficacy in treating CVS, however, its scientific level of
evidence has not exceeded level II.
The causes underlying the clinical observation of
enhanced CBF and improved clinical outcome by
vasopressor-induced hypertension in patients suffering from
CVS have remained uncertain. During CVS the main
cerebral vasculature resistance is shifted from the small
arterioles to the narrowed major cerebral vessels. The
vascular capacity of auto-regulation is impaired in the
cerebral branches supplied by the narrowed arteries [11,
25]. CBF through the narrowed vessels thus becomes the
limiting factor for the cerebral perfusion. Based on the
Hagen-Poiseuille law of laminar flow, CBF may be
manipulated by blood pressure gradient, vessel diameter
and blood viscosity. So far, the enhanced CBF observed as
a result of induced hypertension has been suggested to be
dependent on the increase in blood pressure gradient alone
[18, 21, 24]. Our data, however, demonstrate a significant
dilatation of the narrowed vessels during NE-induced
hypertension in an experimental SAH model. Therefore,
we suggest that the clinical effect observed is additionally
dependent on the dilating effect on the spastic vessel
(Fig. 3). The significant increase in vessel diameter, along
with the significant increase in blood pressure gradient,
may, thus, cause the enhanced CBF and improved clinical
outcome observed in the clinical studies during
vasopressor-induced hypertension. The mechanism itself
of the dilatory effect of NE-induced hypertension on the
vessel diameter remains unclear and is subject to further
investigation. Hypothetically, a haemodynamic effect might
be possible as consequence of direct adrenergic effects on
the cerebral vasculature. The pathophysiology of CVS,
however, is likely to play a minor role in the dilatory effect
observed in our study. The relative dilatory effect of NE-
induced hypertension on the BA in SAH animals was
merely insignificantly greater than in controls.
Finally, some limitations of this study have to be
mentioned. Firstly, the study is limited in providing data
about a possible linear relation between blood pressure
increase and vasodilatation effect due to single point
assessment at high MAP values. Thus, our results are
limited in serving for extrapolation to low and very
moderate states of induced hypertension. Secondly, our
study does not provide data evaluating the consistency over
the time of the vasodilatation effects observed; this aspect is
subject to further investigation.
Conclusion
This study demonstrates that NE-induced hypertension
therapy significantly dilates the vasospastic basilar artery in
a SAH rabbit model. This angiographic finding may possibly
serve as an additional explanation for the enhanced CBF and
improved clinical outcome observed during vasopressor-
induced hypertension therapy in patients suffering from CVS.
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